REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system ...
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
Morning Overview on MSN
Gene hacking is coming and it could rewrite what it means to be human
For the first time, the tools to rewrite human biology are moving from speculative fiction into regulated clinics and ...
A U.S. clinical-stage genome editing company headquartered in Cambridge, Massachusetts. The company runs global clinical ...
Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.
Understanding human gene function in living organisms has long been hampered by fundamental differences between species.
AI‑driven protein design creates potent anti‑CRISPR inhibitors that block Cas13 activity, offering a new potential tool for safer, more controlled gene editing.
Growing focus on gene-based therapies, advances in editing tools, and increasing research investments are accelerating the adoption of genome editing technologies across life sciences and agriculture.
CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...
Some scientists who argue for deregulation deny outdoor gene editing is possible. But patents and the scientific literature ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results